Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGN-104 in Low-grade Upper Tract Urothelial Cancer
NCT06774131Phase 3Recruiting
- Sponsor
- UroGen Pharma
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of Mitomycin C RTGel in upper tract urothelial carcinoma (UTUC), sponsored by UroGen Pharma. Primary endpoint: Complete response rate at 3 months. Started Aug 2025; status: recruiting.
02
Drugs
Mitomycin C RTGel
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06774131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774131.